PDT Partners LLC Purchases Shares of 42,100 Biohaven Ltd. $BHVN

PDT Partners LLC bought a new stake in Biohaven Ltd. (NYSE:BHVN) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 42,100 shares of the company’s stock, valued at approximately $626,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Janus Henderson Group PLC lifted its stake in Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after acquiring an additional 16,127,247 shares in the last quarter. BlackRock Inc. purchased a new stake in Biohaven in the 2nd quarter worth about $196,574,000. Suvretta Capital Management LLC lifted its stake in shares of Biohaven by 83.0% during the 4th quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company’s stock valued at $116,140,000 after buying an additional 4,666,666 shares in the last quarter. Infinitum Asset Management LLC lifted its holdings in Biohaven by 267.6% during the 4th quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company’s stock worth $70,562,000 after purchasing an additional 4,550,000 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in Biohaven by 50.3% during the 4th quarter. Stifel Financial Corp now owns 9,939,856 shares of the company’s stock worth $112,221,000 after acquiring an additional 3,328,506 shares during the period. Institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BHVN. Bank of America restated an “underperform” rating and set a $11.00 price objective (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Biohaven in a research report on Friday, June 26th. Needham & Company LLC set a $11.00 price objective on Biohaven in a research report on Monday, June 29th. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a research report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biohaven presently has an average rating of “Moderate Buy” and an average target price of $18.94.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Up to $795 million in deal value: SK Biopharmaceuticals will pay Biohaven upfront and milestone payments totaling as much as $795 million, in addition to tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. The agreement improves Biohaven’s liquidity, reduces the company’s future development costs for the program and could extend its cash runway. Biohaven and SK Biopharmaceuticals licensing agreement
• Positive Sentiment: External validation of the epilepsy program: The global partnership gives SK Biopharmaceuticals commercialization rights while allowing Biohaven to retain royalty economics. Opakalim is in Phase 2/3 development for focal epilepsy, providing a significant potential value catalyst if clinical results are successful. Reuters Biohaven SK Biopharmaceuticals deal
• Positive Sentiment: Favorable legal ruling: Biohaven also received a favorable ruling in a trade-secret misappropriation lawsuit, improving its legal position and potentially supporting recovery related to the dispute. Biohaven favorable trade-secret ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026, as well as a separate obesity-program readout. These events could determine whether the partnership’s milestone payments and future royalty opportunity are realized. Biohaven epilepsy licensing deal and obesity trial readout

Biohaven Trading Down 5.1%

NYSE:BHVN opened at $16.08 on Friday. Biohaven Ltd. has a one year low of $7.48 and a one year high of $18.57. The company has a debt-to-equity ratio of 21.23, a current ratio of 4.73 and a quick ratio of 4.73. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -3.47 and a beta of 1.26. The business has a fifty day moving average price of $14.79 and a 200-day moving average price of $11.86.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). Sell-side analysts forecast that Biohaven Ltd. will post -3.29 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.